Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma

A pilot study

Marilyn J. Siegel, Clint E. Jokerst, Dhana Rajderkar, Charles F. Hildebolt, Sagun Goyal, Farrokh Dehdashti, Nina Wagner-Johnston, Barry A. Siegel

Research output: Contribution to journalArticle

Abstract

The aim of this study was to compare diffusion-weighted MRI (DW-MRI) with positron emission tomography/computed tomography (PET/CT) for the staging and evaluation of the treatment response in patients with diffuse large B-cell lymphoma (DLBCL). Institutional review board approval was obtained for this study; all subjects gave informed consent. Twelve patients were imaged before treatment and eight of these were also imaged after two cycles of chemotherapy using both DW-MRI and PET/CT. Up to six target lesions were selected at baseline for response assessment based on International Working Group criteria (nodes>1.5cm in diameter; extranodal lesions>1cm in diameter). For pretreatment staging, visual analysis of the numbers of nodal and extranodal lesions based on PET/CT was performed. For interim response assessment after cycle 2 of chemotherapy, residual tumor sites were assessed visually and the percentage changes in target lesion size, maximum standardized uptake value (SUVmax) and apparent diffusion coefficient (ADC) from pretreatment values were calculated. In 12 patients studied pretreatment, there were 46 nodal and 16 extranodal sites of lymphomatous involvement. Agreement between DW-MRI and PET/CT for overall lesion detection was 97% (60/62 tumor sites; 44/46 nodal and 16/16 extranodal lesions) and, for Ann Arbor stage, it was 100%. In the eight patients who had interim assessment, five of their 49 tumor sites remained abnormal on visual analysis of both DW-MRI and PET/CT, and there was one false positive on DW-MRI. Of their 24 target lesions, the mean pretreatment ADC value, tumor size and SUVmax were 772μm2/s, 21.3cm2 and 16.9g/mL, respectively. At interim assessment of the same 24 target lesions, ADC values increased by 85%, tumor size decreased by 74% and SUVmax decreased by 83% (all p

Original languageEnglish (US)
Pages (from-to)681-691
Number of pages11
JournalNMR in Biomedicine
Volume27
Issue number6
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Diffusion Magnetic Resonance Imaging
Lymphoma, Large B-Cell, Diffuse
Magnetic resonance imaging
Positron emission tomography
Cells
Tomography
Tumors
Neoplasms
Chemotherapy
Drug Therapy
Research Ethics Committees
Residual Neoplasm
Informed Consent
Positron Emission Tomography Computed Tomography
Therapeutics

Keywords

  • Apparent diffusion coefficient
  • Diffuse large B-cell lymphoma
  • Diffusion-weighted MRI
  • Positron emission tomography/computed tomography (PET/CT)
  • Response to chemotherapy
  • Standardized uptake value

ASJC Scopus subject areas

  • Spectroscopy
  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Siegel, M. J., Jokerst, C. E., Rajderkar, D., Hildebolt, C. F., Goyal, S., Dehdashti, F., ... Siegel, B. A. (2014). Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: A pilot study. NMR in Biomedicine, 27(6), 681-691. https://doi.org/10.1002/nbm.3105

Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma : A pilot study. / Siegel, Marilyn J.; Jokerst, Clint E.; Rajderkar, Dhana; Hildebolt, Charles F.; Goyal, Sagun; Dehdashti, Farrokh; Wagner-Johnston, Nina; Siegel, Barry A.

In: NMR in Biomedicine, Vol. 27, No. 6, 2014, p. 681-691.

Research output: Contribution to journalArticle

Siegel, MJ, Jokerst, CE, Rajderkar, D, Hildebolt, CF, Goyal, S, Dehdashti, F, Wagner-Johnston, N & Siegel, BA 2014, 'Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: A pilot study', NMR in Biomedicine, vol. 27, no. 6, pp. 681-691. https://doi.org/10.1002/nbm.3105
Siegel, Marilyn J. ; Jokerst, Clint E. ; Rajderkar, Dhana ; Hildebolt, Charles F. ; Goyal, Sagun ; Dehdashti, Farrokh ; Wagner-Johnston, Nina ; Siegel, Barry A. / Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma : A pilot study. In: NMR in Biomedicine. 2014 ; Vol. 27, No. 6. pp. 681-691.
@article{60f59848fdf84e91a5d6af69805b7f71,
title = "Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: A pilot study",
abstract = "The aim of this study was to compare diffusion-weighted MRI (DW-MRI) with positron emission tomography/computed tomography (PET/CT) for the staging and evaluation of the treatment response in patients with diffuse large B-cell lymphoma (DLBCL). Institutional review board approval was obtained for this study; all subjects gave informed consent. Twelve patients were imaged before treatment and eight of these were also imaged after two cycles of chemotherapy using both DW-MRI and PET/CT. Up to six target lesions were selected at baseline for response assessment based on International Working Group criteria (nodes>1.5cm in diameter; extranodal lesions>1cm in diameter). For pretreatment staging, visual analysis of the numbers of nodal and extranodal lesions based on PET/CT was performed. For interim response assessment after cycle 2 of chemotherapy, residual tumor sites were assessed visually and the percentage changes in target lesion size, maximum standardized uptake value (SUVmax) and apparent diffusion coefficient (ADC) from pretreatment values were calculated. In 12 patients studied pretreatment, there were 46 nodal and 16 extranodal sites of lymphomatous involvement. Agreement between DW-MRI and PET/CT for overall lesion detection was 97{\%} (60/62 tumor sites; 44/46 nodal and 16/16 extranodal lesions) and, for Ann Arbor stage, it was 100{\%}. In the eight patients who had interim assessment, five of their 49 tumor sites remained abnormal on visual analysis of both DW-MRI and PET/CT, and there was one false positive on DW-MRI. Of their 24 target lesions, the mean pretreatment ADC value, tumor size and SUVmax were 772μm2/s, 21.3cm2 and 16.9g/mL, respectively. At interim assessment of the same 24 target lesions, ADC values increased by 85{\%}, tumor size decreased by 74{\%} and SUVmax decreased by 83{\%} (all p",
keywords = "Apparent diffusion coefficient, Diffuse large B-cell lymphoma, Diffusion-weighted MRI, Positron emission tomography/computed tomography (PET/CT), Response to chemotherapy, Standardized uptake value",
author = "Siegel, {Marilyn J.} and Jokerst, {Clint E.} and Dhana Rajderkar and Hildebolt, {Charles F.} and Sagun Goyal and Farrokh Dehdashti and Nina Wagner-Johnston and Siegel, {Barry A.}",
year = "2014",
doi = "10.1002/nbm.3105",
language = "English (US)",
volume = "27",
pages = "681--691",
journal = "NMR in Biomedicine",
issn = "0952-3480",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma

T2 - A pilot study

AU - Siegel, Marilyn J.

AU - Jokerst, Clint E.

AU - Rajderkar, Dhana

AU - Hildebolt, Charles F.

AU - Goyal, Sagun

AU - Dehdashti, Farrokh

AU - Wagner-Johnston, Nina

AU - Siegel, Barry A.

PY - 2014

Y1 - 2014

N2 - The aim of this study was to compare diffusion-weighted MRI (DW-MRI) with positron emission tomography/computed tomography (PET/CT) for the staging and evaluation of the treatment response in patients with diffuse large B-cell lymphoma (DLBCL). Institutional review board approval was obtained for this study; all subjects gave informed consent. Twelve patients were imaged before treatment and eight of these were also imaged after two cycles of chemotherapy using both DW-MRI and PET/CT. Up to six target lesions were selected at baseline for response assessment based on International Working Group criteria (nodes>1.5cm in diameter; extranodal lesions>1cm in diameter). For pretreatment staging, visual analysis of the numbers of nodal and extranodal lesions based on PET/CT was performed. For interim response assessment after cycle 2 of chemotherapy, residual tumor sites were assessed visually and the percentage changes in target lesion size, maximum standardized uptake value (SUVmax) and apparent diffusion coefficient (ADC) from pretreatment values were calculated. In 12 patients studied pretreatment, there were 46 nodal and 16 extranodal sites of lymphomatous involvement. Agreement between DW-MRI and PET/CT for overall lesion detection was 97% (60/62 tumor sites; 44/46 nodal and 16/16 extranodal lesions) and, for Ann Arbor stage, it was 100%. In the eight patients who had interim assessment, five of their 49 tumor sites remained abnormal on visual analysis of both DW-MRI and PET/CT, and there was one false positive on DW-MRI. Of their 24 target lesions, the mean pretreatment ADC value, tumor size and SUVmax were 772μm2/s, 21.3cm2 and 16.9g/mL, respectively. At interim assessment of the same 24 target lesions, ADC values increased by 85%, tumor size decreased by 74% and SUVmax decreased by 83% (all p

AB - The aim of this study was to compare diffusion-weighted MRI (DW-MRI) with positron emission tomography/computed tomography (PET/CT) for the staging and evaluation of the treatment response in patients with diffuse large B-cell lymphoma (DLBCL). Institutional review board approval was obtained for this study; all subjects gave informed consent. Twelve patients were imaged before treatment and eight of these were also imaged after two cycles of chemotherapy using both DW-MRI and PET/CT. Up to six target lesions were selected at baseline for response assessment based on International Working Group criteria (nodes>1.5cm in diameter; extranodal lesions>1cm in diameter). For pretreatment staging, visual analysis of the numbers of nodal and extranodal lesions based on PET/CT was performed. For interim response assessment after cycle 2 of chemotherapy, residual tumor sites were assessed visually and the percentage changes in target lesion size, maximum standardized uptake value (SUVmax) and apparent diffusion coefficient (ADC) from pretreatment values were calculated. In 12 patients studied pretreatment, there were 46 nodal and 16 extranodal sites of lymphomatous involvement. Agreement between DW-MRI and PET/CT for overall lesion detection was 97% (60/62 tumor sites; 44/46 nodal and 16/16 extranodal lesions) and, for Ann Arbor stage, it was 100%. In the eight patients who had interim assessment, five of their 49 tumor sites remained abnormal on visual analysis of both DW-MRI and PET/CT, and there was one false positive on DW-MRI. Of their 24 target lesions, the mean pretreatment ADC value, tumor size and SUVmax were 772μm2/s, 21.3cm2 and 16.9g/mL, respectively. At interim assessment of the same 24 target lesions, ADC values increased by 85%, tumor size decreased by 74% and SUVmax decreased by 83% (all p

KW - Apparent diffusion coefficient

KW - Diffuse large B-cell lymphoma

KW - Diffusion-weighted MRI

KW - Positron emission tomography/computed tomography (PET/CT)

KW - Response to chemotherapy

KW - Standardized uptake value

UR - http://www.scopus.com/inward/record.url?scp=84899943545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899943545&partnerID=8YFLogxK

U2 - 10.1002/nbm.3105

DO - 10.1002/nbm.3105

M3 - Article

VL - 27

SP - 681

EP - 691

JO - NMR in Biomedicine

JF - NMR in Biomedicine

SN - 0952-3480

IS - 6

ER -